Uncategorized

Elon Musk’s Ketamine use can’t be probed in OpenAI fraud trial – The Mercury News

By Isaiah Poritz, Bloomberg

Elon Musk’s use of the drug ketamine will be off limits to attorneys for OpenAI Inc. and its chief executive officer Sam Altman during an upcoming jury trial over claims that the generative AI company defrauded Musk by abandoning its nonprofit roots.

US District Judge Yvonne Gonzalez Rogers at a Friday hearing in Oakland, California, traced the contours of the high-profile trial — which will feature live testimony from Silicon Valley’s biggest names in AI — with a series of rulings about what evidence, topics, and witnesses can be presented to the jury.

The trial, scheduled to begin April 28, will revisit the founding years of OpenAI a decade ago, its falling out with Musk and Microsoft Corp.’s subsequent $13 billion investment in the startup.

The jury will determine whether OpenAI’s other co-founders, Altman and Greg Brockman, lied about their intentions to maintain a nonprofit structure when Musk initially donated $38 million to the startup. OpenAI has moved quickly in the past year to convert to a for-profit structure to allow for greater financial flexibility and investments.

Visited 2 times, 2 visit(s) today

Leave a Reply

Your email address will not be published. Required fields are marked *